ADCETRIS Drug Profile

Summary for Tradename: ADCETRIS

High Confidence Patents:	41
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for ADCETRIS

Recent Clinical Trials for ADCETRIS

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Lepu Medical Technology (Beijing) Co., Ltd.	PHASE1
Jiyan Liu	PHASE1
West China Hospital	PHASE1

See all ADCETRIS clinical trials

Pharmacology for ADCETRIS

Mechanism of Action	CD30-directed Antibody Interactions
Physiological Effect	Microtubule Inhibition
Established Pharmacologic Class	CD30-directed Immunoconjugate
Chemical Structure	Immunoconjugates

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ADCETRIS Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ADCETRIS Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Seagen Inc.	ADCETRIS	brentuximab vedotin	For Injection	125388		2032-07-25	DrugPatentWatch analysis and company disclosures
Seagen Inc.	ADCETRIS	brentuximab vedotin	For Injection	125388		2037-05-30	DrugPatentWatch analysis and company disclosures
Seagen Inc.	ADCETRIS	brentuximab vedotin	For Injection	125388		2036-05-16	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for ADCETRIS Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Seagen Inc.	ADCETRIS	brentuximab vedotin	For Injection	125388		2035-05-11	Patent claims search
Seagen Inc.	ADCETRIS	brentuximab vedotin	For Injection	125388		2035-07-16	Patent claims search
Seagen Inc.	ADCETRIS	brentuximab vedotin	For Injection	125388		2036-08-10	Patent claims search

International Patents for ADCETRIS

Country	Patent Number	Estimated Expiration
Mexico	380738
Denmark	2893004
Japan	2020192388

Market Dynamics and Financial Trajectory for ADCETRIS

Last updated: February 20, 2026

What is ADCETRIS and its current market position?

ADCETRIS (brentuximab vedotin) is a CD30-directed antibody-drug conjugate developed by Seattle Genetics. Approved by the FDA in 2011 for relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma, it competes primarily in the hematologic malignancy space. The drug's approval has expanded to include several other indications, emphasizing its importance in targeted lymphoma therapy.

How does ADCETRIS generate revenue?

In fiscal year 2022, ADCETRIS generated $405 million in worldwide net product sales, representing an increase of approximately 10% compared to 2021. Revenue stems from two primary sources: royalty payments from development partners and direct sales from Seattle Genetics' commercial operations, predominantly in North America and Europe.

Year	Net Sales (USD Millions)	Year-over-Year Growth
2020	$370	9%
2021	$368	-0.5%
2022	$405	10%

(Seattle Genetics annual filings, 2022)

What are the key drivers influencing ADCETRIS's market dynamics?

Clinical pipeline expansion

ADCETRIS's efficacy data in multiple new indications can influence future market growth. It is being investigated for:

• Peripheral T-cell lymphomas (phase III ongoing)
• Cutaneous T-cell lymphoma (phase III ongoing)
• Solid tumors such as non-small cell lung cancer (NSCLC) in combination with other agents

Regulatory landscape

The presence of regulatory approvals across major markets accelerates its adoption. The drug has received approval in over 50 countries. Key approvals include:

• FDA (2011)
• European Medicines Agency (EMA, 2012)
• Japan’s PMDA (2013)

Competitive environment

ADCETRIS faces competition from:

• Polivy (polatuzumab vedotin, Roche)
• Blincyto (blinatumomab)
• New antibody-drug conjugates (ADCs) entering development

The competitive landscape pressures pricing and reimbursement decisions, impacting market share.

Strategic partnerships

Seattle Genetics collaborates with Takeda Pharmaceuticals for commercialization outside North America. This partnership influences regional sales growth and access, especially in Asian markets.

What are the financial risks and opportunities?

Revenue growth potential

Market expansion into new indications and combination therapies can boost revenue. For example, ongoing trials in frontline Hodgkin lymphoma and novel ADCs combining ADCETRIS with immune checkpoint inhibitors hold promise.

Patent protection and biosimilars

ADCETRIS's key patents extend until 2028, with patent challenges ongoing in certain jurisdictions. The emergence of biosimilars could lead to price erosion post-patent expiry.

Cost considerations

Investments in manufacturing scale-up, supply chain resilience, and new formulation development increase operational costs. These investments aim to improve margins and facilitate supply sufficiency for expanded indications.

Pricing and reimbursement

Pricing varies significantly across geographies due to differing healthcare systems. For example, in the US, the wholesale acquisition cost (WAC) is approximately $7,400 per 50mg vial. Reimbursement policies impact revenue realization and access.

What is the outlook through 2025 and beyond?

The forecast indicates a compound annual growth rate (CAGR) of approximately 8% for ADCETRIS sales from 2022 to 2025, driven by:

• Approval in additional indications (expected in 2024)
• Increased adoption in combination regimens
• Expansion into emerging markets

However, growth may face headwinds from:

• Patent expirations
• New competitors
• Reimbursement challenges

Seattle Genetics projects revenues from ADCETRIS to reach about $500 million by 2025.

Conclusion

ADCETRIS maintains a strong position within the lymphoma treatment landscape, supported by ongoing clinical development and strategic alliances. Its financial trajectory is favorable, contingent on successful expansion into new indications, regulatory approvals, and management of competitive and pricing pressures.

---

Key Takeaways

• ADCETRIS generated $405 million in 2022, with stable growth driven by expanded indications and international markets.
• The drug’s patent life until 2028 represents a window for revenue growth and market penetration.
• Competition from other ADCs and biosimilars presents pricing and market share risks.
• Clinical trial advances boost future sales prospects, particularly in treatment combinations and earlier lines.
• Reimbursement policies and regional healthcare systems substantially influence revenue streams.

---

FAQs

1. When is ADCETRIS expected to face biosimilar competition?
   Likely around 2028, following patent expiration, contingent on patent challenges and biosimilar development timelines.

2. What new indications could drive ADCETRIS revenue?
   Frontline Hodgkin lymphoma, peripheral T-cell lymphomas, and combination therapies with immune checkpoint inhibitors.

3. How does regional regulation affect ADCETRIS sales?
   Regulatory approvals in over 50 countries facilitate market access; reimbursement policies influence patient access and revenue.

4. What are the risks associated with ADCETRIS's clinical trials?
   Unsuccessful trial outcomes in key indications could delay approval, limiting sales growth.

5. What are Seattle Genetics's strategies for maintaining ADCETRIS's competitiveness?
   Expanding indications, forming new partnerships, investing in clinical research, and optimizing manufacturing capacities.

---

References

[1] Seattle Genetics. (2022). Annual report.
[2] U.S. Food and Drug Administration. (2011). ADCETRIS approval letter.
[3] European Medicines Agency. (2012). ADCETRIS marketing authorization.
[4] ClinicalTrials.gov. (2023). Ongoing studies involving ADCETRIS.